BTK and B-cell chronic lymphocytic leukemia: First-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib was the first of this class of drugs introduced as a central therapeutic agent for chronic lymphocytic leukemia (CLL), ushering in the era of kinase-targeting medications for this disease (Burger and Chiorazzi, 2013).